However, Karakashev et al. demonstrated that combination treatment with BET inhibition suppressed TOPBP1 and WEE1 expression, resulting in accumulation of DNA damage, checkpoint defects, and apoptosis in preclinical models of BRCA-wild type ovarian cancer [15]. The gene discussed is TOPBP1; the disease is ovarian carcinoma.